Biohaven Pharmaceutical Holding Co Ltd.(BHVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BHVN Biohaven Pharmaceutical Holding Co Ltd.

Market Closed 11-13 16:00:00 EST

13.82

-0.25

-1.78%

盘后13.80

-0.02-0.14%

19:59 EST

High14.29	Low13.37	Vol1.26M
Open14.29	D1 Closing14.07	Amplitude6.54%
Mkt Cap2.08B	Tradable Cap1.63B	Total Shares150.42M
T/O17.32M	T/O Rate1.07%	Tradable Shares117.99M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BHVN","market":"US","secType":"STK","nameCN":"Biohaven Pharmaceutical Holding Co Ltd.","latestPrice":13.82,"timestamp":1794603600000,"preClose":14.07,"halted":0,"volume":1257764,"hourTrading":{"tag":"盘后","latestPrice":13.8,"preClose":13.82,"latestTime":"19:59 EST","volume":20929,"amount":289135.21,"timestamp":1794617964082,"change":-0.02,"changeRate":-0.001447,"amplitude":0.001447},"delay":0,"changeRate":-0.0177683013503909,"floatShares":117986353,"shares":150417084,"eps":-3.810562,"marketStatus":"Market Closed","change":-0.25,"latestTime":"11-13 16:00:00 EST","open":14.29,"high":14.29,"low":13.37,"amount":17322986.103052,"amplitude":0.065387,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.810562,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1794819600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1493870400000,"exchange":"NYSE","adjPreClose":14.07,"preHourTrading":{"tag":"盘前","latestPrice":14.5,"preClose":14.07,"latestTime":"09:06 EST","volume":1574,"amount":22322.077648,"timestamp":1794578768994,"change":0.43,"changeRate":0.030561,"amplitude":0.199005},"postHourTrading":{"tag":"盘后","latestPrice":13.8,"preClose":13.82,"latestTime":"19:59 EST","volume":20929,"amount":289135.21,"timestamp":1794617964082,"change":-0.02,"changeRate":-0.001447,"amplitude":0.001447},"volumeRatio":0.543914128147446,"impliedVol":1.2137,"impliedVolPercentile":0.8805},"requestUrl":"/m/hq/s/BHVN/wiki","defaultTab":"wiki","newsList":[{"id":"2683563383","title":"Will Graves Disease Trial Progress Change Biohaven (BHVN) Stock Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2683563383","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683563383?lang=en_us&edition=fundamental","pubTime":"2026-11-14 17:39","pubTimestamp":1794649183,"startTime":"0","endTime":"0","summary":"AAl BentleyNovember 14, 2026","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/will-graves-disease-trial-progress-change-biohaven-bhvn-stoc","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/will-graves-disease-trial-progress-change-biohaven-bhvn-stoc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2065732104.USD","LU1093756168.USD","PRGS","BK4139","BHVN","BK4097","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682200628","title":"Is Biohaven (BHVN) Cheap As Pipeline Progress And The Ono Deal Lift Interest?","url":"https://stock-news.laohu8.com/highlight/detail?id=2682200628","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682200628?lang=en_us&edition=fundamental","pubTime":"2026-11-09 10:28","pubTimestamp":1794191334,"startTime":"0","endTime":"0","summary":"BBailey PembertonNovember 9, 2026","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/is-biohaven-bhvn-cheap-as-pipeline-progress-and-the-ono-deal","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/is-biohaven-bhvn-cheap-as-pipeline-progress-and-the-ono-deal","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2065732104.USD","LU1093756168.USD","PRGS","LU1093756325.SGD","BK4097","BHVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681811046","title":"How Pivotal Graves Trial Will Impact Biohaven Stock (BHVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2681811046","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681811046?lang=en_us&edition=fundamental","pubTime":"2026-11-07 16:35","pubTimestamp":1794040531,"startTime":"0","endTime":"0","summary":"SSasha JovanovicNovember 7, 2026","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/how-pivotal-graves-trial-will-impact-biohaven-stock-bhvn","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/how-pivotal-graves-trial-will-impact-biohaven-stock-bhvn","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1093756168.USD","BHVN","BK4139","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681020435","title":"Biohaven Enrolls Patients in Phase 3 Trial of BHV-1300 for Graves' Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2681020435","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681020435?lang=en_us&edition=fundamental","pubTime":"2026-11-05 20:38","pubTimestamp":1793882326,"startTime":"0","endTime":"0","summary":"Biohaven Enrolls Patients in Phase 3 Trial of BHV-1300 for Graves' DiseaseBiohaven is enrolling patients in a pivotal Phase 3 trial of BHV-1300 for Graves' disease at more than 55 US and Canadian site","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nNDL2ZkJPt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","BHVN","BK4139","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679229612","title":"Biohaven Price Target Raised to $32.00/Share from $21.00 by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2679229612","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679229612?lang=en_us&edition=fundamental","pubTime":"2026-10-31 08:40","pubTimestamp":1793407200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BHVN/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","BK4139","LU1093756168.USD","BHVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679293244","title":"Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN), Supernus Pharmaceuticals (SUPN) and Alignment Healthcare (ALHC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2679293244","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679293244?lang=en_us&edition=fundamental","pubTime":"2026-10-31 02:30","pubTimestamp":1793385015,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biohaven Ltd. (BHVN), Supernus Pharmaceuticals (SU...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-biohaven-ltd-bhvn-supernus-pharmaceuticals-supn-and-alignment-healthcare-alhc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-biohaven-ltd-bhvn-supernus-pharmaceuticals-supn-and-alignment-healthcare-alhc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1093756168.USD","BK4539","BK4581","LABU","XLV","SUPN","BHVN","XBI","BK4007","BK4588","BK4585","LU1093756325.SGD","BK4154","ALHC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679293151","title":"US Research Roundup-Amazon, Caterpillar, Intel","url":"https://stock-news.laohu8.com/highlight/detail?id=2679293151","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679293151?lang=en_us&edition=fundamental","pubTime":"2026-10-30 16:54","pubTimestamp":1793350473,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP-Amazon, Caterpillar, IntelOct 30 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including Amazon, Caterpillar and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261030:nL3N46G0UZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CFR","BAC","AMZD","COIN","CTSH","INTC","CAT","BBIO","APG","BWFG","ALGM","BXMT","CDNA","AJG","AMRZ","COMP","AOS","BNY","BELFB","OWL","BG","FTAG","CHDN","ALRM","CTVA","AEP","AIN","AGCO","DTRE","AMZY","BSX","ALNY","BC","ARES","ALRS","WTRE","AMZN","BLDR","BHVN","PRVT","FIAT","KROP","IYG","BMY","CARR","FINX","CROX","FTXO","ADAM","AMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679236492","title":"Biohaven Q3 Adj. EPS $(0.73) Beats $(0.74) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2679236492","media":"Benzinga Earnings","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679236492?lang=en_us&edition=fundamental","pubTime":"2026-10-30 04:17","pubTimestamp":1793305022,"startTime":"0","endTime":"0","summary":"Biohaven (NYSE:BHVN) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.74) by 1.35 percent. This is a 50.34 percent increase over losses of $(1.47) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/10/62718879/biohaven-q3-adj-eps-0-73-beats-0-74-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","LU1093756168.USD","BHVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679023666","title":"Biohaven Q3 2026 Net Loss Narrows 25% to $129.28 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2679023666","media":"Reuters","labels":["corporation","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679023666?lang=en_us&edition=fundamental","pubTime":"2026-10-30 04:13","pubTimestamp":1793304796,"startTime":"0","endTime":"0","summary":"Biohaven Q3 2026 net loss narrows 25% to $129.28 millionBiohaven’s third-quarter 2026 net loss narrowed 25% year over year to $129.28 million.Research and development expenses fell 28% to $101.85 mill","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261029:nNDL8l2HyP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BHVN","BK4139","LU1093756168.USD","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679823307","title":"Biohaven Q3 Basic EPS USD -0.86","url":"https://stock-news.laohu8.com/highlight/detail?id=2679823307","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679823307?lang=en_us&edition=fundamental","pubTime":"2026-10-30 04:02","pubTimestamp":1793304120,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261029:nPLXWJ0ZGP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1093756168.USD","LU1093756325.SGD","BHVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679330932","title":"Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2679330932","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679330932?lang=en_us&edition=fundamental","pubTime":"2026-10-30 04:02","pubTimestamp":1793304120,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261029:nTUA58JKTC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BHVN","LU1093756168.USD","LU1093756325.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678435827","title":"RBC Capital Sticks to Its Hold Rating for Biohaven Ltd. (BHVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2678435827","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678435827?lang=en_us&edition=fundamental","pubTime":"2026-10-28 09:56","pubTimestamp":1793152601,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Leonid Timashev from RBC Capital maintained a Hold rating on Biohaven Ltd., with a price target of $22.00. Timashev...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-hold-rating-for-biohaven-ltd-bhvn-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-hold-rating-for-biohaven-ltd-bhvn-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BHVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678579160","title":"Biohaven's BHV-1420 Reduces Disease-Driving Antibodies by over 90% in Mouse Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2678579160","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678579160?lang=en_us&edition=fundamental","pubTime":"2026-10-26 19:32","pubTimestamp":1793014355,"startTime":"0","endTime":"0","summary":"Biohaven's BHV-1420 reduces disease-driving antibodies by over 90% in mouse studyBiohaven presented preclinical results for BHV-1420 in membranous nephropathy at ASN Kidney Week on Oct. 24, 2026.Labor","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261026:nNDL2hshld:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","BHVN","BK4139","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678185595","title":"Biohaven (BHVN) As FDA Review And Ono Deal Revive The Buying Opportunity Question","url":"https://stock-news.laohu8.com/highlight/detail?id=2678185595","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678185595?lang=en_us&edition=fundamental","pubTime":"2026-10-25 05:29","pubTimestamp":1792877347,"startTime":"0","endTime":"0","summary":"Regulatory momentum and new licensing deal reshape the Biohaven story\nBiohaven (BHVN) has been back in focus after the FDA agreed to review its resubmitted application for Vyglxia in spinocerebellar ataxia and scheduled an advisory committee meeting, while a new Ono Pharmaceutical licensing deal added fresh attention to its pipeline.\nThat FDA decision and the Ono deal arrived alongside sharp trading swings, with Biohaven’s share price dropping 5.5% on the day to US$13.88 after a recent 7 day...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/biohaven-bhvn-as-fda-review-and-ono-deal-revive-the-buying-o","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/biohaven-bhvn-as-fda-review-and-ono-deal-revive-the-buying-o","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1093756168.USD","BK4588","BK4585","BK4139","BHVN","LU1093756325.SGD","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677997193","title":"Does FDA Review Acceptance Change The Bull Case For Biohaven Stock (BHVN)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2677997193","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677997193?lang=en_us&edition=fundamental","pubTime":"2026-10-24 00:36","pubTimestamp":1792773366,"startTime":"0","endTime":"0","summary":"Biohaven reported that the FDA accepted its resubmitted new drug application for Vyglxia, or troriluzole, in spinocerebellar ataxia and disclosed a licensing deal with Ono Pharmaceutical for its MoDE pan IgG degrader portfolio in selected Asian markets.\nThe combination of a defined FDA review path and an IgG degrader partnership gives Biohaven a clearer view on potential future indications, regional responsibilities, and development funding needs across its late-stage and early pipeline...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/does-fda-review-acceptance-change-the-bull-case-for-biohaven","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/does-fda-review-acceptance-change-the-bull-case-for-biohaven","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK4139","LABU","LU1093756168.USD","BK4588","LU1093756325.SGD","BHVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677197666","title":"Biohaven Could Transform With Troriluzole's FDA Approval, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2677197666","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677197666?lang=en_us&edition=fundamental","pubTime":"2026-10-23 23:56","pubTimestamp":1792770974,"startTime":"0","endTime":"0","summary":"Biohaven  securing approval for troriluzole could transform the company, potentially unlocking a $1.24 billion opportunity, RBC Capital Markets said Thursday.The US Food and Drug Administration has accepted the company's resubmitted new drug application for troriluzole in spinocerebellar ataxia, a group of rare, genetic neurological disorders, with a Q1 2027 target action date and an advisory committee meeting, the brokerage noted.Troriluzole \"has a real shot to be approved\" and the advisory committee is likely to be a key determining factor in the approval, RBC said. However, risks to the approval remain given the product candidate's imperfect data package and uncertainties with the committee vote, the investment firm added.The estimated $1.24 billion out year opportunity assumes a 2027 launch, RBC said, adding the drug has the potential to capture about 10% of the patient population the same year and then grow to 30% by 2029.RBC has a sector perform rating on Biohaven, with a price t","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BHVN","BK4585","LABU","LU1093756168.USD","BK4139","LU1093756325.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677242299","title":"Biohaven Ltd. (BHVN) Receives a Buy from Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2677242299","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677242299?lang=en_us&edition=fundamental","pubTime":"2026-10-23 20:10","pubTimestamp":1792757444,"startTime":"0","endTime":"0","summary":"In a report released today, Sumant Kulkarni from Canaccord Genuity reiterated a Buy rating on Biohaven Ltd., with a price target of $21.00. Accordi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/biohaven-ltd-bhvn-receives-a-buy-from-canaccord-genuity-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/biohaven-ltd-bhvn-receives-a-buy-from-canaccord-genuity-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1093756168.USD","BHVN","LU1093756325.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677210639","title":"RBC Capital Sticks to Its Hold Rating for Biohaven Ltd. (BHVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2677210639","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677210639?lang=en_us&edition=fundamental","pubTime":"2026-10-23 19:59","pubTimestamp":1792756755,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Leonid Timashev from RBC Capital maintained a Hold rating on Biohaven Ltd., with a price target of $22.00. The comp...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-hold-rating-for-biohaven-ltd-bhvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-hold-rating-for-biohaven-ltd-bhvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BHVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677250519","title":"RBC Raises Price Target on Biohaven to $22 From $19, Keeps Sector Perform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2677250519","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677250519?lang=en_us&edition=fundamental","pubTime":"2026-10-23 18:50","pubTimestamp":1792752648,"startTime":"0","endTime":"0","summary":"Biohaven (BHVN) has an average rating of overweight and mean price target of $25.17, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1093756325.SGD","BK4139","LU1093756168.USD","BHVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677499079","title":"US Research Roundup- Amgen, Lockheed Martin, Norfolk Southern","url":"https://stock-news.laohu8.com/highlight/detail?id=2677499079","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677499079?lang=en_us&edition=fundamental","pubTime":"2026-10-23 15:54","pubTimestamp":1792742091,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP- Amgen, Lockheed Martin, Norfolk SouthernOct 23 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including Amgen, L","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261023:nL4N4690L5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASB","ATRO","BBT","AMAL","BE","AARD","PYZ","ABT","BNTC","TMED","BX","XYZ","SAM","APPF","BILL","APD","JETS","AGNC","AOSL","DVDN","OZK","CTEC","AAL","BANR","BARC.UK","BMI","AMGN","AFRM","AVAH","BFH","BHVN","AXGN","BEX","BHB","CF","BOOT","BC","ACM","AAP","BYD","ASAN","XYZY","ARR","PSP","PJP","PINE","BSY","AVTX","VEGI","AMPL"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biohaven.com","stockEarnings":[{"period":"1week","weight":-0.0456},{"period":"1month","weight":0.2644},{"period":"3month","weight":-0.056},{"period":"6month","weight":0.5776},{"period":"1year","weight":0.7104},{"period":"ytd","weight":0.2241}],"compareEarnings":[{"period":"1week","weight":0.0259},{"period":"1month","weight":-0.0198},{"period":"3month","weight":-0.0283},{"period":"6month","weight":0.0206},{"period":"1year","weight":0.1225},{"period":"ytd","weight":0.1062}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.071849},{"month":2,"riseRate":0.222222,"avgChangeRate":-0.026101},{"month":3,"riseRate":0.222222,"avgChangeRate":-0.120539},{"month":4,"riseRate":0.555556,"avgChangeRate":0.027819},{"month":5,"riseRate":0.666667,"avgChangeRate":0.144578},{"month":6,"riseRate":0.6,"avgChangeRate":0.085557},{"month":7,"riseRate":0.5,"avgChangeRate":0.000445},{"month":8,"riseRate":0.7,"avgChangeRate":0.052139},{"month":9,"riseRate":0.7,"avgChangeRate":0.073808},{"month":10,"riseRate":0.6,"avgChangeRate":-0.049346},{"month":11,"riseRate":0.3,"avgChangeRate":-0.048681},{"month":12,"riseRate":0.555556,"avgChangeRate":0.054983}],"exchange":"NYSE","name":"Biohaven Pharmaceutical Holding Co Ltd.","nameEN":"Biohaven Pharmaceutical Holding Co Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biohaven Pharmaceutical Holding Co Ltd.(BHVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biohaven Pharmaceutical Holding Co Ltd.(BHVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biohaven Pharmaceutical Holding Co Ltd.,BHVN,Biohaven Pharmaceutical Holding Co Ltd.股票,Biohaven Pharmaceutical Holding Co Ltd.股票老虎,Biohaven Pharmaceutical Holding Co Ltd.股票老虎国际,Biohaven Pharmaceutical Holding Co Ltd.行情,Biohaven Pharmaceutical Holding Co Ltd.股票行情,Biohaven Pharmaceutical Holding Co Ltd.股价,Biohaven Pharmaceutical Holding Co Ltd.股市,Biohaven Pharmaceutical Holding Co Ltd.股票价格,Biohaven Pharmaceutical Holding Co Ltd.股票交易,Biohaven Pharmaceutical Holding Co Ltd.股票购买,Biohaven Pharmaceutical Holding Co Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biohaven Pharmaceutical Holding Co Ltd.(BHVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biohaven Pharmaceutical Holding Co Ltd.(BHVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}